NAS10026,906−5.38%S&P7,400−3.75%GOLD$4,127+1.33%BTC$76,159−5.28%VIX24.13+45.27%latest tape · as of 20:03 UTC
The Screen · Consumer Cyclical · Furnishings, Fixtures & Appliances
SGISomnigroup International Inc
SGI · the NYSE · USD · Market cap $14.3B · 19,000 employees
Somnigroup International Inc., together with its subsidiaries, designs, manufactures, distributes, and retails bedding products in the United States and internationally.
FAIL · Does not pass the screen
69.81 USD
Price as of 4 Nov 2026Daily close, not a live quote
Screened 2026-11-04 · the tape above runs as of 20:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price69.81 USD at the 4 Nov 2026 close
Our value readUndervalued vs our fair value, as of 4 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.12, read 2026-11-01
Ethical does not pass the values gate
Price69.81 USD
Fair value89.95
Ethical score70.0/100
Value readUndervaluedas of 4 Nov 2026
Our investment reviews on this name
2026-11-01Read Markup63.56+9.8% to today ✓Accumulation gives way to Markup first Markup read since September
2026-10-25Read Accumulation62.04+12.5% to today ✓Markdown gives way to Accumulation
2026-10-11Read Markdown62.34+12.0% to today Distribution gives way to Markdown with volume flow in agreement
2026-10-02Read Distribution63.36+10.2% to today Markup gives way to Distribution after a 7% slide in 3 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Somnigroup International Inc holds its Markup at $69.81. The statistical read favours the buyers, held for 1 days.
As held on the ledger · 2026-11-04
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 1 days
Price at the screen
$69.81
Valuation
24.75 trailing · 16.10 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.24
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
57.54%
Below 33%
Interest-bearing debt is 57.5% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
4.25%
Below 49%
Money owed to the company is 4.3% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Somnigroup International's business is in a permissible area, but its interest-bearing debt is about 58% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when SGI's ethical verdict changes
Today SGI does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 4 Nov 2026: it trades at roughly a 27% discount to our $89.95 fair value, narrow competitive moat.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. A 22.4% discount to the base estimate.
Where our models see it going: fair-value estimate $89.95, with a range of $72.00 to $106.13, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Mattress Sales Track Boom and Bust Cycles
Picture a household weighing up a new mattress only when bonuses land or house prices rise. Somnigroup sits right in that discretionary corner of consumer spending. Revenue is growing at 12 percent with an 18 percent return on equity, yet the opportunity rating sits at none because the business stays tied to economic swings.
The narrow moat and 7 percent profit margin show a workable but unexceptional operation. Forward earnings sit at 18.7 times while analysts cluster around a 98 dollar target. Those figures do not overcome the fact that peak-cycle earnings often flatter multiples and leave investors holding lower profits when spending slows.
Currency moves and housing data can shift demand fast, and a narrow moat offers little defence once wallets close. Ethical checks clear but the cyclical trap remains the dominant issue. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
SGI trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Markup$69.81+6.8%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 6.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (8 analysts) rates it strong buy, with a mean price target of $97. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-04Markup$65.35+2.8%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (8 analysts) rates it strong buy, with a mean price target of $97. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Markup$63.56+0.0%Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (8 analysts) rates it strong buy, with a mean price target of $97. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Markup$63.56+0.0%Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (8 analysts) rates it strong buy, with a mean price target of $97. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Markup · changed$63.56+2.5%Entry 10
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (8 analysts) rates it strong buy, with a mean price target of $97.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (8 analysts) rates it strong buy, with a mean price target of $97.
2026-10-18Markdown$62.04-0.5%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (8 analysts) rates it strong buy, with a mean price target of $97.
2026-10-11Markdown · changed$62.34-1.6%Entry 7
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (8 analysts) rates it strong buy, with a mean price target of $97.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 6.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (8 analysts) rates it strong buy, with a mean price target of $97. Since the last review it its composite score rose.
2026-09-12Markup · changed$67.82-5.9%Entry 5
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 5.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (8 analysts) rates it strong buy, with a mean price target of $97.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.